
Everolimus 1 mg Tablets, 60 Tablets/Bottle
- Manufacturer:
- HIKMA PHARMACEUTICALS USA INC
- Form
- TABLET
- Unit size
- 60
- Strength
- 1MG
Details
Details
Everolimus — 1MG, Tablet, bottle of 60 tablets
Everolimus is a tablet for oral use. Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients: • Kidney Transplant : at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids. ( 1.1 ) • Liver Transplant : Administer no earlier than 30 days posttransplant.
- Active ingredient or product type: EVEROLIMUS
- Strength/concentration: 1MG
- Dosage form and route: Tablet, Oral
- Exact package presentation: bottle of 60 tablets
- NDC/item number: 0054-0604-21
- Manufacturer: HIKMA PHARMACEUTICALS USA INC
- Storage/handling: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature]. Protect from light and moisture.
- Status: Rx only
Important safety information: • Angioedema [increased risk with concomitant angiotensin converting enzyme (ACE inhibitors)] : Monitor for symptoms and treat promptly. ( 5.8 ) • Delayed wound healing/fluid accumulation : Monitor symptoms; treat promptly to minimize complications. ( 5.9 ) • Interstitial lung disease (ILD)/Non-infectious pneumonitis : Monitor for symptoms or radiologic changes; manage by dose reduction or discontinuation until symptoms resolve; consider use of corticosteroids. ( 5.10 ) • Hyperlipidemia (elevati
Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.